Psychosis recognition and early intervention: the AU general practice approach

Psychosis in the GP setting

For most people, the first contact when psychotic symptoms develop is a general practitioner — not a psychiatrist, and not an emergency department. The consultation might be framed by the patient as “I haven’t been sleeping well” or “things just feel strange,” or it might be a parent who has noticed their teenager withdrawing from friends and failing school. Recognising the possibility of an emerging psychotic illness early — before the full episode becomes entrenched — is one of the highest-impact things a GP can do in mental health care.

The evidence from Orygen’s EPPIC research program and the international OPUS and RAISE trials is consistent: duration of untreated psychosis (DUP) is the single strongest modifiable predictor of long-term outcome. Shorter DUP is associated with better symptomatic recovery, faster remission, improved vocational functioning, and lower hospitalisation rates. Every week a young person spends in an untreated psychotic state carries measurable cost to their recovery trajectory. GPs who recognise early and refer promptly are intervening at the point where intervention makes the most difference.

This article covers the recognition of psychosis and its prodrome, the initial workup, the early intervention model in Australia, treatment principles, and the GP’s ongoing role in physical health monitoring.

A. Core clinical — the AU general-practice framework

What psychosis is and what it is not

Psychosis refers to a syndrome of impaired reality testing characterised by one or more of:

• Delusions — fixed false beliefs held with conviction despite contrary evidence; persecutory, referential, grandiose, somatic, or relating to thought interference or control
• Hallucinations — perceptions without stimulus; auditory hallucinations (voices) are most characteristic of schizophrenia; visual, tactile, and olfactory hallucinations more commonly suggest organic or substance-related causes
• Disorganised thinking — loose associations, tangentiality, derailment, or in severe cases, word salad
• Grossly disorganised or catatonic behaviour
• Negative symptoms — avolition, anhedonia, alogia, affective flattening, social withdrawal

Psychosis is a syndrome, not a diagnosis. The underlying diagnosis — schizophrenia, schizoaffective disorder, substance-induced psychosis, psychosis due to a general medical condition, brief psychotic disorder — is established after careful workup.

The prodromal phase

Months to years before threshold psychotic symptoms, most people experience an at-risk mental state (ARMS) or clinical high-risk (CHR-P) phase. Features are non-specific but clinically recognisable:

• Unexplained significant decline in academic or work performance
• New or intensifying social withdrawal without obvious cause
• Unusual perceptual experiences (“things feel dreamlike,” “voices seem muffled or strange”)
• Sub-threshold suspicious or odd beliefs the person can still partially test
• Persistent anxiety, depression, or irritability refractory to standard treatment
• Sleep disturbance
• Deteriorating self-care

The CAARMS (Comprehensive Assessment of At-Risk Mental States) criteria operationalise this; Orygen and headspace Early Psychosis services can apply these formally. As a GP, the appropriate action when you notice these features in a young person is to refer to the early intervention service rather than waiting to confirm a diagnosis.

Initial assessment priorities

When a person presents with possible first-episode psychosis, structure the initial assessment around:

1. Risk — suicidality (5–10% lifetime completed suicide in schizophrenia, highest in early years), risk to others, self-neglect, vulnerability to exploitation
2. Capacity — ability to consent and to engage with care
3. Organic exclusion — medical and substance causes must be ruled out before attributing symptoms to a primary psychotic disorder
4. Functional impact — how severely is daily life affected?
5. Social context — family support, accommodation, employment, trauma history

Differential diagnosis — do not miss organic causes

The eTG psychotropic chapter and NICE CG178 both emphasise that organic causes of psychosis must be actively excluded. Key differentials:

• Substance-induced — methamphetamine, cannabis (especially high-potency), synthetic cannabinoids, LSD, MDMA, cocaine, alcohol withdrawal; also corticosteroids, dopaminergic agents used in Parkinson’s disease, anticholinergics, levetiracetam
• Autoimmune encephalitis — anti-NMDA receptor encephalitis is critically important to recognise; classically in young women, may have teratoma, presents with movement disorder, autonomic instability, and seizures alongside psychiatric features; check anti-NMDA receptor antibodies when atypical features are present
• Delirium — fluctuating level of consciousness, inattention, visual hallucinations more common than auditory; medical illness usually identifiable
• Mood disorder with psychotic features — major depression or mania with mood-congruent psychosis
• Temporal lobe epilepsy — ictal and postictal psychosis; focal neurological symptoms; history of seizures
• CNS infection — HIV, neurosyphilis, viral encephalitis
• Endocrine disorders — hyperthyroidism, Cushing’s syndrome, Addison’s crisis, hypoglycaemia
• Metabolic — hyponatraemia, hypercalcaemia, uraemia, hepatic encephalopathy
• Brain tumour, stroke, traumatic brain injury

B. Early intervention — what the evidence shows

The early intervention model

Australia has world-leading early psychosis infrastructure. Orygen in Melbourne pioneered the EPPIC (Early Psychosis Prevention and Intervention Centre) model, which demonstrated through rigorous research that specialised, intensive, early-phase treatment produces substantially better outcomes than standard care. The model comprises:

• Assertive case management by a consistent clinical team
• Low-dose second-generation antipsychotic therapy
• CBT for psychosis (CBTp)
• Family psychoeducation and family work
• Supported education and employment (Individual Placement and Support model)
• Peer support workers
• Harm-reduction approach to substance use
• Proactive physical health monitoring

headspace Early Psychosis (hEP) extends this model to approximately 14 metropolitan centres across Australia, primarily for young people aged 12–25. State-funded EPPIC equivalents operate in various forms in most states.

Antipsychotic medication — principles

Second-generation antipsychotics are first-line for first-episode psychosis. Key principles from RANZCP guidelines:

• Start low, go slow — people with first-episode psychosis are more sensitive to antipsychotics and typically respond at lower doses than people with established schizophrenia
• Allow adequate trial time — 4–6 weeks at a therapeutic dose before declaring treatment failure; some response may be gradual
• Choose based on side-effect profile and patient preference — aripiprazole and ziprasidone have lower metabolic burden; olanzapine is highly effective but causes more weight gain and metabolic dysregulation
• Long-acting injectable (LAI) antipsychotics — aripiprazole monthly (Abilify Maintena), paliperidone palmitate monthly or three-monthly (Invega Sustenna, Trinza), risperidone fortnightly — should be considered early for adherence, not only after demonstrated non-adherence

Psychosocial treatments

CBT for psychosis (CBTp) is a standard component of care — it reduces symptom distress and improves coping, though it is an adjunct to medication rather than a replacement. Family intervention (psychoeducation, communication training, expressed-emotion reduction) reduces relapse and hospitalisation. Supported employment using the Individual Placement and Support (IPS) model improves real-world employment outcomes significantly.

C. Cardiometabolic health — the mortality gap

The 15–20 year premature mortality in schizophrenia is predominantly from preventable cardiovascular disease — not from suicide, as is often assumed. NPS MedicineWise and RANZCP both emphasise that cardiometabolic care is part of psychosis management, not separate from it.

Mandatory monitoring

Per eTG, at baseline and every 3–6 months on antipsychotics:

• Weight and BMI
• Waist circumference
• Blood pressure
• Fasting lipids
• Fasting glucose and HbA1c
• ECG if QT-prolonging agent used
• Prolactin (with risperidone, paliperidone, or first-generation antipsychotics)

Specific clozapine monitoring: full blood count weekly for 18 weeks, then monthly for life — managed through the Australian Clozapine Patient Monitoring System. Troponin and ECG at 4 weeks (myocarditis surveillance). Constipation surveillance — clozapine-induced bowel obstruction has caused deaths and is often under-recognised.

Smoking cessation

Approximately 50% of people with schizophrenia smoke — roughly double the general population rate. Smoking is the largest single contributor to the cardiovascular mortality gap. Varenicline is the most effective pharmacotherapy and is well-tolerated in schizophrenia despite historical concerns about neuropsychiatric effects — the FDA resolved those concerns after the large EAGLES trial. Nicotine replacement therapy and behavioural support are also appropriate and should be offered proactively at every contact.

D. Australian operations

MBS items for psychosis management

MBS Online items relevant to psychosis care in general practice:

• Items 23/36/44 — standard consultation levels B, C, D
• Items 2715/2717 — Mental Health Treatment Plan (preparation and review)
• Items 80000–80020 — Better Access psychology (10 sessions per year)
• Item 81335 — telehealth psychology
• Items 132/133 — consultant physician (psychiatry) initial and subsequent
• Items 291/293 — psychiatrist consultation
• Items 965/967 — GPCCMP (Chronic Condition Management Plan) for cardiometabolic care in established illness
• Item 715 — ATSI Health Assessment (includes mental health screening)

PBS prescribing authority

Most antipsychotics require Authority (Streamlined or telephone) for PBS subsidy with a schizophrenia or psychosis indication. Relevant PBS items:

• Oral olanzapine, risperidone, paliperidone — Authority Required (Streamlined)
• Aripiprazole, quetiapine — Authority Required (Streamlined or telephone)
• Paliperidone palmitate LAI (Invega Sustenna, Trinza) — Authority Required for schizophrenia
• Aripiprazole LAI (Abilify Maintena) — Authority Required
• Clozapine — Authority Required, specialist initiation, mandatory monitoring system

Crisis pathways

Each state and territory has a 24-hour mental health crisis line — Vic 1300 369 012, NSW 1800 011 511, Qld 1300 642 255, SA 13 14 65, WA 1800 676 822. For acute psychosis with risk, the emergency department under the relevant Mental Health Act is the appropriate pathway.

Community supports

SANE Australia provides peer support, education, and resources. Mental Illness Fellowship of Australia (MIFA) supports families and carers. NDIS eligibility applies for persistent psychosocial disability impairing daily function in those under 65.

E. Special populations

Adolescents — onset in adolescence often disrupts education and social development at critical periods. NICE CG155 provides guidance on psychosis in children and young people; dose considerations, safeguarding, and family involvement are particularly important. headspace and Orygen both serve adolescents.

Women of reproductive age — antipsychotics vary in teratogenic risk; clozapine and olanzapine have more data than newer agents. Prolactin elevation from some antipsychotics can suppress ovulation; women may assume they cannot become pregnant. Contraceptive counselling and preconception planning are part of holistic care.

Substance use — methamphetamine and cannabis are the most commonly encountered complicating substances in Australian practice. Substance-induced psychosis can be clinically indistinguishable from primary psychosis in the acute phase. A harm-reduction approach to substance use is standard; abstinence from cannabis is advice supported by evidence given its strong dose-response relationship with psychosis risk and course.

Cultural and linguistic diversity — psychosis presentations and explanatory models vary across cultural backgrounds. Interpreter services and culturally safe assessment are important, particularly in the refugee and migrant populations who are disproportionately represented in first-episode services.

When to escalate

Refer or escalate urgently when:

• Suicidal ideation with plan or intent, or command hallucinations directing self-harm
• Active homicidal ideation
• Severe agitation or aggression risking safety
• Suspected catatonia — benzodiazepine challenge (lorazepam IM) is first-line; ECT for refractory catatonia
• Suspected neuroleptic malignant syndrome — fever, rigidity, autonomic instability, raised CK; medical emergency
• Suspected autoimmune encephalitis — urgent neurology or immunology workup
• Any acute delirium or organic cause suspected — acute medical workup
• First-episode psychosis in a young person — refer to headspace Early Psychosis or equivalent for specialist assessment

What this article is and is not

This is general health information drawn from Australian and international clinical guidelines — RANZCP, Orygen Early Psychosis Clinical Guidelines, NICE CG178/CG155, eTG Psychotropic, and headspace program literature. It is not personal medical advice and does not create a doctor–patient relationship. Treatment decisions for people with psychotic illness require specialist mental health input; GPs play a vital role in recognition, physical health, and coordination but should work alongside psychiatry and early intervention services rather than managing psychotic illness independently.

If you or someone you know needs support: Lifeline 13 11 14 (available 24 hours), Beyond Blue 1300 22 4636, or 13YARN 13 92 76 (First Nations peoples, 24 hours). For a mental health emergency: call 000 or go to the nearest emergency department.

For consumer support: SANE Australia, HealthDirect — Psychosis, or state mental health crisis lines.

---

Sources cited

1. RANZCP — Clinical Practice Guidelines for Schizophrenia and Related Disorders
2. Orygen — Early Psychosis Clinical Guidelines
3. headspace — Early Psychosis programs
4. Therapeutic Guidelines (eTG) — Psychotropic: schizophrenia and psychosis
5. Australian Medicines Handbook
6. NICE CG178 — Psychosis and schizophrenia in adults
7. NICE CG155 — Psychosis and schizophrenia in children and young people
8. NPS MedicineWise — Antipsychotic medications
9. RACGP — Mental health resources
10. HealthDirect — Psychosis
11. SANE Australia
12. MBS Online